LINC01163

Across TCGA pan-cancer cohorts, LINC01163 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of LINC01163’s most consistent transcriptional readouts.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where LINC01163 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC01163 is over-expressed in tumor, although a few such as LUSC show the opposite, repressed pattern.

UCEC, BRCA, and STAD are the cancer types where LINC01163 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC01163 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
UCEC	All	All	+0.820	<.001	6	view →
BRCA	All	II,III,IV	+0.037	.001	4	view →
STAD	All	All	+0.113	.011	3	view →
KIRC	Male	All	+0.031	<.001	3	view →
LIHC	Female	All	+0.025	.008	2	view →
HNSC	All	All	+0.021	.015	2	view →
PRAD	All	All	+0.008	.026	2	view →
LUSC	Male	III,IV	−0.052	.009	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

LINC01163–UCEC

Open the UCEC breakdown →